Complain about a product or service

FDA Wants Stronger Warnings on Sleep Disorder Drugs

Drugs Can Cause "Sleep Driving" Incidents

March 15, 2007

Sleep • Sleep Apnea Can Be Dangerous • Afternoon Nap May Help Long-Term Memory • Lack of Deep Sleep May Increase Diabetes Risk • Sleepless in America • Sleep Disorders Can Hurt Kids' Grades • A Good Night's Sleep Essential to Heart Health • FDA Wants Stronger Warnings on Sleep Disorder Drugs • Sleep Apnea Common but Undiagnosed Among Pacemaker Patients • Americans May Be Relying Too Heavily on Sleeping Pills • Body Clock Findings May Help With Jet Lag, Insomnia • Sleep Apnea Heightens Risk of Stroke and Death • Nighttime Dying Linked to Sleep Apnea From Brain Cell Loss • Study Identifies Sleep Disorder Warning Signs In Kids • Laser Surgery and Sleep Apnea • Snore Formula Settles Federal Charges • Infomercial Doctor Agrees to Stifle SNORenz Claims

The U.S. Food and Drug Administration wants tougher language on drugs for sleep disorders, beefing up the warnings to consumers about potential risks.

The sedative-hypnotic drug products -- a class of drugs used to induce and maintain sleep -- carry risks of severe allergic reactions and complex sleep-related behaviors, which may include sleep-driving, the agency said.

Sleep driving is defined as driving while not fully awake after ingestion of a sedative-hypnotic product, with no memory of the event.

A year ago Rep. Patrick Kennedy (D-RI) was involved in a highly publicized mishap, crashing his car into a barricade at the U.S. Capitol. He was taking the sleep disorder drug Ambien at the time.

"There are a number of prescription sleep aids available that are well-tolerated and effective for many people," said Steven Galson, M.D., MPH, director of FDA’s Center for Drug Evaluation and Research. "However, after reviewing the available post-marketing adverse event information for these products, FDA concluded that labeling changes are necessary to inform health care providers and consumers about risks."

In December 2006, FDA sent letters to manufacturers of products approved for the treatment of sleep disorders requesting that the whole class of drugs revise product labeling to include warnings about the following potential adverse events:

• Anaphylaxis (severe allergic reaction) and angioedema (severe facial swelling), which can occur as early as the first time the product is taken.

• Complex sleep-related behaviors which may include sleep-driving, making phone calls, and preparing and eating food (while asleep).

FDA said it has been working with the product manufacturers over the past three months to update labeling, notify health care providers and inform consumers of these risks.

Along with the labeling revisions, FDA has requested that each product manufacturer send letters to health care providers to notify them about the new warnings. Manufacturers will begin sending these letters to providers starting this week.

In addition, FDA said it has requested that manufacturers of sedative-hypnotic products develop Patient Medication Guides for the products to inform consumers about risks and advise them of potential precautions that can be taken. Patient Medication Guides are handouts given to patients, families and caregivers when a medicine is dispensed.

The guides will contain FDA-approved information such as proper use and the recommendation to avoid ingesting alcohol and/or other central nervous system depressants. When these Medication Guides are available, patients being treated with sleep medications should read the information before taking the product and talk to their doctors if they have questions or concerns. Patients should not discontinue the use of these medications without first consulting their health care provider.

Although all sedative-hypnotic products have these risks, the agency said there may be differences among products in how often they occur. For this reason, FDA has recommended that the drug manufacturers conduct clinical studies to investigate the frequency with which sleep-driving and other complex behaviors occur in association with individual drug products.

The medications that are the focus of the revised labeling include the following 13 products:

Ambien/Ambien CR (Sanofi Aventis)
Butisol Sodium (Medpointe Pharm HLC)
Carbrital (Parke-Davis)
Dalmane (Valeant Pharm)
Doral (Questcor Pharms)
Halcion (Pharmacia & Upjohn)
Lunesta (Sepracor)
Placidyl (Abbott)
Prosom (Abbott)
Restoril (Tyco Healthcare)
Rozerem (Takeda)
Seconal (Lilly)
Sonata (King Pharmaceuticals)

Report Your Experience
If you've had a bad experience -- or a good one -- with a consumer product or service, we'd like to hear about it. All complaints are reviewed by class action attorneys and are considered for publication on our site. Knowledge is power! Help spread the word. File your consumer report now.